2025 Annual Meeting | N4 - Neuroscience in the Clinic: Time for Tau: Developments in Biomarkers and Therapeutic Trials

Date Tuesday 04/08/25

Time 01:00 PM - 03:00 PM PDT Add To Calendar

Location San Diego Convention Center | 31AB

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Neuroscience in the Clinic Session

Director(s) Vijay K. Ramanan, MD, PhD, Sharon Sha, MD

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives Participants should become familiar with recent advances in neuroimaging and fluid (blood and cerebrospinal fluid) biomarkers relevant for assessing tau pathology in neurodegenerative disease, as well as gain awareness of extant clinical trial approaches targeting tau pathology for disease modification in Alzheimer's and related disorders.

This program is supported in part by an educational grant from Roche Diagnostics.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Didactic

Program Materials Program Evaluations

Event Timeline
01:00 PM - 01:05 PM PDT	Introduction	Introduction Vijay K. Ramanan, MD, PhD, Sharon Sha, MD
01:05 PM - 01:25 PM PDT	Speaker	Tau Imaging Elizabeth Mormino, PhD
01:25 PM - 01:35 PM PDT	Abstract	001 - Role of 18F-Florzolotau PET in Diagnostic and Therapeutic Decision-Making for Cognitive Impairment Jin-Tai Yu, PhD
01:35 PM - 01:45 PM PDT	Abstract	002 - Whole-brain functional connectivity predicts tau PET in preclincal Alzheimer’s disease Hamid Abuwarda
01:45 PM - 02:05 PM PDT	Speaker	Fluid Biomarkers Relevant for Tau Pathology Nicolas R. Barthélemy, PhD
02:05 PM - 02:15 PM PDT	Abstract	003 - Evaluation of Plasma pTau217 plus Abeta42/40, and pTau217/Abeta42 Ratio as Confirmatory Tests for Amyloid Pathology in Alzheimer’s Disease (AD) John Winslow, PhD
02:15 PM - 02:35 PM PDT	Speaker	Clinical Development of Tau-targeting Therapies for Neurodegenerative Disease Adam L. Boxer, MD, PhD
02:35 PM - 03:00 PM PDT	Q&A	Q&A Vijay K. Ramanan, MD, PhD, Sharon Sha, MD, Elizabeth Mormino, PhD, Nicolas R. Barthélemy, PhD

Faculty Disclosures
Vijay K. Ramanan, MD, PhD	The institution of Dr. Ramanan has received research support from the National Institutes of Health. The institution of Dr. Ramanan has received research support from the Mangurian Foundation for Lewy Body Disease Research. The institution of Dr. Ramanan has received research support from as part of clinical trials sponsored by the Alzheimer's Association, Eisai, the Alzheimer's Treatment and Research Institute at USC, and Transposon Therapeutics, Inc.. The institution of Dr. Ramanan has received research support from Medscape. The institution of Dr. Ramanan has received research support from Expert Perspectives in Medicine. Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving as a Conference Speaker/Organizer (Honoraria) with AANI.
Sharon Sha, MD	Dr. Sha has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global. Dr. Sha has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ExpertConnect. Dr. Sha has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Sha has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cognition Therapeutics. Dr. Sha has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Forefront Collaborative. Dr. Sha has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ReachMD. Dr. Sha has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for PeerView. Dr. Sha has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medscape. The institution of Dr. Sha has received research support from Biogen. The institution of Dr. Sha has received research support from Jannssen. The institution of Dr. Sha has received research support from UCB Pharma. The institution of Dr. Sha has received research support from Eisai. The institution of Dr. Sha has received research support from Eli Lilly. The institution of Dr. Sha has received research support from Aribio. Dr. Sha has received publishing royalties from a publication relating to health care.
Elizabeth Mormino, PhD	Elizabeth Mormino, PhD has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurotrack. Elizabeth Mormino, PhD has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. The institution of Elizabeth Mormino, PhD has received research support from NIH. The institution of Elizabeth Mormino, PhD has received research support from Alzheimer's Association. The institution of Elizabeth Mormino, PhD has received research support from Simons Foundation. The institution of Elizabeth Mormino, PhD has received research support from Archer Foundation.
Nicolas R. Barthélemy, PhD	No disclosure on file
Adam L. Boxer, MD, PhD	An immediate family member of Dr. Boxer has received personal compensation for serving as an employee of Kaiser Permanente. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono. Dr. Boxer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Oscotec. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arrowhead. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine Biosciences. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Switch. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arvinas. Dr. Boxer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alector. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Boxer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Boxer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Transposon. Dr. Boxer has stock in Alector. Dr. Boxer has stock in Arvinas. Dr. Boxer has stock in Neurovanda. The institution of Dr. Boxer has received research support from Biogen. The institution of Dr. Boxer has received research support from Eisai. The institution of Dr. Boxer has received research support from Regeneron. The institution of Dr. Boxer has received research support from NIH. The institution of Dr. Boxer has received research support from Bluefield Project. Dr. Boxer has received research support from Rainwater Charitable Foundation.
Hamid Abuwarda	Mr. Abuwarda has nothing to disclose.
Anne Trainer	Anne Trainer has nothing to disclose.
Corey Horien, MD, PhD	Dr. Horien has nothing to disclose.
Xilin Shen, PhD	The institution of Dr. Shen has received research support from NIH.
Suyeon Ju	Suyeon Ju has nothing to disclose.
Todd Constable	Todd Constable has nothing to disclose.
Carolyn Fredericks, MD	The institution of Dr. Fredericks has received research support from Alzheimer's Association. The institution of Dr. Fredericks has received research support from National Institute on Aging.
Jin-Tai Yu, PhD	Prof. Yu has nothing to disclose.
John Winslow, PhD	Dr. Winslow has received personal compensation for serving as an employee of Labcorp/Monogram Biosciences. Dr. Winslow has received personal compensation for serving as an employee of Labcorp/Monogram Biosciences. Dr. Winslow has stock in Labcorp. Dr. Winslow has received intellectual property interests from a discovery or technology relating to health care.
Ahmed Chenna, PhD	Dr. Chenna has received personal compensation for serving as an employee of LabCorp-monogram Biosciences. Dr. Chenna has stock in LabCorp.
Mintzu Lo	Mintzu Lo has received personal compensation for serving as an employee of Labcorp.
Youssouf Badal	Youssouf Badal has nothing to disclose.
Brandon Yee	Brandon Yee has received personal compensation for serving as an employee of Labcorp. Brandon Yee has stock in Lacborp.
Robert Martone, Other	Mr. Martone has received personal compensation for serving as an employee of Labcorp. Mr. Martone has stock in Pfizer. Mr. Martone has stock in AbbVie. Mr. Martone has stock in Labcorp.
Christos J. Petropoulos, PhD	Dr. Petropoulos has received personal compensation for serving as an employee of Labcorp-Monogram Biosciences. Dr. Petropoulos has stock in Laboratory Corporation of America Holdings. Dr. Petropoulos has received intellectual property interests from a discovery or technology relating to health care.
Christopher Fowler	Christopher Fowler has nothing to disclose.
Simon M. Laws, PhD	The institution of Prof. Laws has received research support from Multiple Sclerosis Western Australia (MSWA). The institution of Prof. Laws has received research support from Eli Lilly.
Stephanie Rainey-Smith, PhD	The institution of Prof. Rainey-Smith has received research support from NHMRC. Prof. Rainey-Smith has received personal compensation in the range of $500-$4,999 for serving as a Grant Assessment Committee Member with NHMRC.
Ralph Martins	No disclosure on file
Christopher Rowe, MD	Dr. Rowe has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Rowe has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Rowe has received research support from Cerveau Technologies. The institution of Dr. Rowe has received research support from Eisai. The institution of Dr. Rowe has received research support from Biogen.
Colin L. Masters, MD	Prof. Masters has nothing to disclose.
James J. Doecke, PhD	Dr. Doecke has nothing to disclose.

��ɫ��

��ɫ��